Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
Standard
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. / Bittner, Stefan; Steffen, Falk; Uphaus, Timo; Muthuraman, Muthuraman; Fleischer, Vinzenz; Salmen, Anke; Luessi, Felix; Berthele, Achim; Klotz, Luisa; Meuth, Sven G; Bayas, Antonios; Paul, Friedemann; Hartung, Hans-Peter; Linker, Ralf; Heesen, Christoph; Stangel, Martin; Wildemann, Brigitte; Then Bergh, Florian; Tackenberg, Björn; Kuempfel, Tania; Weber, Frank; Zettl, Uwe K; Ziemann, Ulf; Tumani, Hayrettin; Groppa, Sergiu; Mühlau, Mark; Lukas, Carsten; Hemmer, Bernhard; Wiendl, Heinz; Gold, Ralf; Zipp, Frauke; KKNMS consortium.
in: EBIOMEDICINE, Jahrgang 56, 06.2020, S. 102807.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
AU - Bittner, Stefan
AU - Steffen, Falk
AU - Uphaus, Timo
AU - Muthuraman, Muthuraman
AU - Fleischer, Vinzenz
AU - Salmen, Anke
AU - Luessi, Felix
AU - Berthele, Achim
AU - Klotz, Luisa
AU - Meuth, Sven G
AU - Bayas, Antonios
AU - Paul, Friedemann
AU - Hartung, Hans-Peter
AU - Linker, Ralf
AU - Heesen, Christoph
AU - Stangel, Martin
AU - Wildemann, Brigitte
AU - Then Bergh, Florian
AU - Tackenberg, Björn
AU - Kuempfel, Tania
AU - Weber, Frank
AU - Zettl, Uwe K
AU - Ziemann, Ulf
AU - Tumani, Hayrettin
AU - Groppa, Sergiu
AU - Mühlau, Mark
AU - Lukas, Carsten
AU - Hemmer, Bernhard
AU - Wiendl, Heinz
AU - Gold, Ralf
AU - Zipp, Frauke
AU - KKNMS consortium
N1 - Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.
AB - BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.
U2 - 10.1016/j.ebiom.2020.102807
DO - 10.1016/j.ebiom.2020.102807
M3 - SCORING: Journal article
C2 - 32460167
VL - 56
SP - 102807
JO - EBIOMEDICINE
JF - EBIOMEDICINE
SN - 2352-3964
ER -